Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / CRSP
Stock rating · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG (CRSP) Stock Rating & Analysis
As of October 6, 2026, MELANY rates CRISPR Therapeutics AG 64 out of 100 (Promising). Its highest factor score is analyst sentiment at 79, and its lowest is business quality at 21.
MELANY ratingRated 2026-10-06CRSP · composite score
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene-editing company developing therapeutics based on Crispr/Cas9, a technology (clustered regularly interspaced short palindromic repeats and Crispr-associated protein 9) for precisely altering specific genomic DNA sequences. The company applies this technology to genetically defined diseases. Its first approved drug, Casgevy, was developed with Vertex Pharmaceuticals and treats sickle-cell disease and transfusion-dependent beta-thalassemia.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why CRSP scores 64/100
CRSP's 8 factor scores run from 21 to 79, and 2 of them sit above its composite of 64. Here is how CRSP breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Analyst targets 61% upside
Near-term events that could move the stock.
- Earnings in 34 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How CRSP compares
As of October 7, 2026, CRISPR Therapeutics AG is tied for 11th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for CRSP
- Operating margin -1128%, cash-burn business, dependent on capital markets
- Negative free cash flow, company consuming cash, not generating it
- Short interest 23% of float, high volatility risk on news
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
CRISPR Therapeutics AG sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 60/100 for strength. Theme strength feeds CRSP's momentum and catalyst factors above.
CRSP trade plan (Pro)
MELANY has a full position plan for CRISPR Therapeutics AG: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates CRSP
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. CRISPR Therapeutics AG's 64/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CRSP
Is CRISPR Therapeutics AG (CRSP) a buy?
As of 2026-10-06, MELANY rated CRISPR Therapeutics AG Promising with a composite score of 64/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is CRISPR Therapeutics AG's MELANY score?
CRISPR Therapeutics AG (CRSP) has a MELANY composite score of 64/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the CRSP stock rating calculated?
MELANY scores CRSP from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy CRISPR Therapeutics AG stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates CRISPR Therapeutics AG (CRSP) Promising with a composite of 64/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CRSP stock price forecast?
MELANY does not publish price targets or forecasts for CRSP. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 64/100 across eight factors for CRISPR Therapeutics AG, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CRSP stock overvalued or undervalued?
MELANY's valuation factor currently reads 63/100 for CRISPR Therapeutics AG, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CRSP's read.
What price should I buy CRSP at?
Rather than chasing the current price, MELANY computes a smart entry zone for CRSP: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying CRSP stock?
The top risks MELANY currently flags for CRISPR Therapeutics AG: Operating margin -1128%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 23% of float, high volatility risk on news; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is CRISPR Therapeutics AG a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 21/100 for CRISPR Therapeutics AG, and earnings track record, at 64/100. The 64/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CRSP stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 61/100 for CRSP right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CRSP rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CRSP continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, CRSP included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.